A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia
| Autor: | David J. King, Steven J. Cooper, M. J. Mitchell, M. Blomqvist, R. C. Montgomery, M. M. Doherty |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male medicine.medical_specialty Placebo-controlled study Relapse prevention Placebo law.invention Randomized controlled trial Extrapyramidal symptoms Double-Blind Method law Recurrence Internal medicine medicine Remoxipride Humans Psychiatry Aged Pharmacology Psychiatric Status Rating Scales Dopamine antagonist Middle Aged Benzamides Chronic Disease Clinical Global Impression Schizophrenia Female medicine.symptom Psychology medicine.drug Antipsychotic Agents |
| Zdroj: | Psychopharmacology. 107(2-3) |
| ISSN: | 0033-3158 |
| Popis: | Sixty-two DSM III chronic schizophrenic inpatients were selected for a double-blind, placebo controlled, multi-centre, relapse prevention study of remoxipride, a selective dopamine (D2)-receptor antagonist. After a 1 month placebo washout, 23 patients had relapsed and were withdrawn. Of the remaining patients 19 were randomised to remoxipride (150-300 mg daily) and 20 to placebo. Their median age was 58 years, 26 were male, and the median duration of illness was 33 years. After 24 weeks a further total of 8 remoxipride and 17 placebo patients had been withdrawn. Excluding three patients withdrawn for reasons other than relapse, the comparative relapse rates were 37% and 75%, respectively (P = 0.015). Efficacy analyses using clinical global impression (P = 0.04) and change in BPRS scores (P = 0.016) were in favour of remoxipride. Extrapyramidal symptoms were minimal in both groups. Treatment emergent adverse events were similar in the two groups. Remoxipride is therefore of potential value as a safe drug which is both effective and well tolerated in the long term management of chronic schizophrenic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink